HBMN:SWX
HBM Healthcare Investments AG
233,50 CHF
arrow_upward
+1,52%(+3,50) 1 d.
29. apr., 09:42:23 GMT+2 · CHF
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: HBMN…
Atvērt
233,50 CHF
Augsta
233,50 CHF
Zema
232,00 CHF
Tirgus kapitalizācija
1,57 mljrd.
Vid. apjoms
6,47 tūkst.
Apjoms
220,00
Dividende
3,21%
Ceturkšņa dividendes
1,88 CHF
Datums, kad tiek pārtraukta dividenžu izmaksa
2025. gada 2. jūl.
Cenas/peļņas attiecība
6,50
Augstākā 52 ned.
245,50 CHF
Zemākā 52 ned.
157,40 CHF
Peļņa uz vienu akciju
35,93 CHF
Apgrozībā esošās akcijas
6,74 milj.
Ziņas un raksti
No avotiem tīmeklī
Simply Wall Street
·
pirms 5 minūtēm
Tenable Flexible Pricing Aims To Boost Tenable One Platform Adoption
Morningstar Canada
·
pirms 9 minūtēm
The S&P 500 Bump That Doesn’t Last
MarketBeat
·
pirms 22 minūtēm
Short Interest in Opera Limited Sponsored ADR (NASDAQ:OPRA) Decreases By 21.6%
Seeking Alpha
·
pirms 47 minūtēm
Nasdaq 100: AI Bubble Fears Overblown, Bullish Trend Intact Above 26,760 Key Intraday Support
Profils
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Par “HBM Healthcare Investments AG”
Ģenerāldirektors-
Darbinieki-
Dibināšanas datums2001. gada 12. jūl.
Galvenais birojsCūga, Cūga, Šveice
Sektors-
Tīmekļa vietnehbmhealthcare.com
MI saturā var būt kļūdas. Uzzināt vairāk